http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-H08183740-A
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5198a2a21392d6cbc0bb4898b3fb3d29 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ead90443277482e25bf91bfddef2b5a7 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 |
filingDate | 1994-12-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5b4d5a605b5d0cd1c002f756f0880d09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_87c8507dbe38376fe01a49775fcdc045 |
publicationDate | 1996-07-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | JP-H08183740-A |
titleOfInvention | Cell adhesion inhibitor and anti-inflammatory agent containing the inhibitor |
abstract | (57) [Summary] [Structure] The following general formula (1): A-Ser-Arg-Gly-Asp-Trp-OH (1) (In the formula, A is orotic acid, hydroorotic acid, pyroglutamic acid, L- Cell adhesion comprising a peptide represented by 2-azetidinecarboxylic acid, proline, a compound selected from the group consisting of 3,4-dehydroproline and sarcosine) or a pharmaceutically acceptable salt thereof as an active ingredient Inhibitor. An anti-inflammatory agent containing the cell adhesion inhibitor as a main component. [Effect] It is extremely useful in industry because it has extremely low toxicity and enables treatment of a wide range of inflammatory diseases involving various white blood cells. |
isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-03061620-A3 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-03061620-A2 |
priorityDate | 1994-12-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 110.